Quantification of residual disease in chronic myelogenous leukemia patients on interferon-α therapy by competitive polymerase chain reaction

Blood

Volumn 87, Issue 4, 1996, Pages 1549-1555

  Hochhaus, Andreas ^b   Lin, Feng ^b   Reiter, Andreas ^b   Skladny, Heyko ^b   Mason, Philip J ^b   Van Rhee, Frits ^b   Shepherd, Patricia C A ^b   Allan, Norman C ^b   Hehlmann, Rüdiger ^b   Goldman, John M ^b   Cross, Nicholas C P ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BUSULFAN; COMPLEMENTARY DNA; CYTARABINE; ETOPOSIDE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HYDROXYUREA; IDARUBICIN; LYMPHOBLAST INTERFERON; MERCAPTOPURINE; RECOMBINANT ALPHA2A INTERFERON; RNA; TIOGUANINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHILD; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; METAPHASE; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS;

EID: 13344250478     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.4.1549.bloodjournal8741549     Document Type: Article

References (26)

1. Daley GQ, van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia by the P210 bcr/abl gene on the Philadelphia chromosome. Science 247:824, 1990
2. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU: Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med 114:532, 1991
3. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, Arthur DD, Powell B, Gottlieb A, Peterson BA, Rai K, Testa JR, LeBeau M, Tantravahi R, Bloomfield CD: Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chrome-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 82:2975, 1993
4. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820, 1994
5. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queißer W, Löffler H, Hochhaus A, Heinze B, Georgii A, Bartram CR, Gricßhammer M, Bergmann L, Essers U, Falge C, Queißer U, Meyer P, Schmitz N, Eimermacher H, Walther F, Fett W, Kleeberg UR, Käbisch A, Nerl C, Zimmermann R, Meuret G, Tichelli A, Kanz L, Tigges FJ, Schmid L, Brockhaus W, Tobler A, Reiter A, Perker M, Emmerich B, Verpoort K, Zankovich R, v Wussow P, Prümmer O, Thiele J, Buhr T, Ansari H, and the German CML Study Group: Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia (CML). Blood 84:4064, 1994
6. Allan NC, Richards SM, Shepherd PCA: UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response. Lancet 345:1392, 1995
7. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M: Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 122:254, 1995
8. Grossman A, Silver RT, Szatroswki, Gutfried A, Verma RS, Benn PA: Densitometric analysis of Southern blot autoradiographs and its application to monitoring patients with chronic myeloid leukemia. Leukemia 5:540, 1991
9. Verschraegen CF, Talpaz M, Hirsch-Ginsberg CF, Pherwani R, Rios MB, Stass SA, Kantarjian HM: Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia. Blood 85:2705, 1995
10. Bentz M, Cabot G, Moos M, Speicher MR, Ganser A, Lichter P, Döhner H: Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization. Blood 83:1922, 1994
11. Zhao L, Kantarjian HM, van Oort J, Cork A, Trujilio JM, Liang JC: Detection of residual proliferating leukemic cells by fluorescence in situ hybridization in CML patients in complete remission after interferon treatment. Leukemia 7:168, 1993
12. Guo JQ, Lian JY, Xian YM, Lee MS, Deisseroth AB, Stass SA, Champlin RE, Talpaz M, Wang YJ, Arlinghaus RB: BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy. Blood 83:3629, 1994
13. Cross NCP, Lin F, Chase A, Bungey J, Hughes TP, Goldman JM: Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82:1929, 1993
14. Lin F, Goldman JM, Cross NCP: A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukaemia. Br J Haematol 86:683, 1994
15. ISCN: An international system for human cytogenetic nomenclature, in Harnden DG, Klinger HP (eds): Basel, Switzerland, Karger, 1985 (published in collaboration with Cancer Genet Cytogenet)
16. Cross NCP, Hughes TP, Lin F, O'Shea P, Bungey J, Marks DI, Ferrant P, Martial P, Goldman JM: Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. Br J Haematol 84:67, 1993
17. Van Rhee F, Marks DI, Lin F, Szydlo RM, Treleaven J, Hochhaus A, Delord C, Cross NCP, Goldman JM: Quantification of residual disease in Philadelphia positive acute lymphoblastic leukemia: Comparison of blood and bone marrow. Leukemia 9:329, 1995
18. Mason PJ, Vulliamy TJ, Foulkes NS, Town M, Haidar B, Luzzatto L: The production of normal and variant human glucose-6-phosphate dehydrogenase in cos cells. Eur J Biochem 178:109, 1988
19. Sambrook J, Frisch EF, Maniatis T (eds): Molecular Cloning: A Laboratory Manual (ed 2). Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1989
20. De Klein A, Hagemeijer A, Bartram CR, Houwen R, Hoefsloot L, Carbonell F, Chan L, Barnett M, Greaves M, Kleihauer E, Heisterkamp N, Groffen J, Grosveld G: Bcr rearrangement and translocation of the c-abl oncogene in Philadelphia positive acute lymphoblastic leukemia. Blood 68:1369, 1986
21. BCR/ABL chronic myeloid leukaemia: The missing link with chronic myelomonocytic leukaemia? Leukemia 8:208, 1994
22. Lin F, Chase A, Bungey J, Goldman JM, Cross NCP: Correlation between the proportion of Philadelphia chromosome-positive metaphase cells and levels of BCR-ABL mRNA in chronic myeloid leukaemia. Genes Chromosome Cancer 13:110, 1995
23. Hook EB: Exclusion of chromosomal mosaicism: Tables of 90%, 95%, and 99% confidence limits and comments on use. Am J Hum Genet 29:94, 1977
24. Hochhaus A, Lin F, Reiter A, Skladny H, van Rhee F, Shepherd PCA, Allan NC, Hehlmann R, Goldman JM, Cross NCP. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-α. Br J Haematol 91:126, 1995
25. Radich JP, Gehly G, Gooley T, Bryant E, Clift RA, Colkins S, Edmands S, Kirk J, Lee A, Kessler P, Schoch G, Buckner CD, Sullivan KM, Appelbaum FR, Thomas ED: Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: Results and implications in 346 patients. Blood 85:2632, 1995
26. Hehlmann R, Heimpel H, Hasford J: Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia: Response to Kantarjian and Talpaz and to Tura and Baccarani. Blood 85:3000, 1995 (letter)